Source: Eli Lilly and Company From: PR Newswire – Immuno-oncology collaboration aims to develop up to five cancer vaccines that target neoantigens across multiple tumor types – CureVac to receive an upfront payment of $50 million and an equity investment of €45 million Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on …
-
-
Love After a Breast Cancer Diagnosis
-
Why I Can’t Write Your Breast Cancer Story for You
-
Moving to a Distant Location as a Breast Cancer Survivor
-
Getting a Second Opinion After a Breast Cancer Diagnosis
-
Dealing with the Side Effects of Breast Cancer Treatments
